Met Life Investment Management, LLC C4 Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 15,477 shares of CCCC stock, worth $92,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,477Holding current value
$92,862% of portfolio
0.0%Shares
22 transactions
Others Institutions Holding CCCC
# of Institutions
122Shares Held
53.8MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$29.3 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$29.1 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$27.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$24.3 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$21.3 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $293M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...